Nurix Therapeutics Inc Aktie News

SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Arthur T. Sands, M.D.

SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced the closing of its previously announced underwritten registered offering of 24,485,799 shares of its common s...

Nurix Therapeutics, Inc. (NASDAQ:NRIX ) Discusses Clinical and Preclinical Updates on BTK, STAT6, and IRAK4 Degrader Programs October 22, 2025 8:00 AM EDT Company Participants Arthur Sands - CEO, President & Director Paula O'Connor - Chief Medical Officer Gwenn Hansen - Chief Scientific Officer Johannes Van Houte - Chief Financial Officer Conference Call Participants Jiale Song - Jefferies LLC,...

SAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced the pricing of its underwritten registered offering of 24,485,799 shares of its common stock at a price of $10...

600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL)

NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint mechanism distinct from PD-1/PD-L1 therapies

Nurix Therapeutics maintains a Strong Buy rating, driven by promising progress with its oral BTK degrader bexobrutideg for relapsed/refractory CLL. NRIX plans to initiate a pivotal single-arm phase 2 study in 2H 2025, potentially enabling Accelerated Approval based on strong phase 1a data (80.9% ORR). Future expansion includes a phase 3 randomized trial and combinations to target 1st- and 2nd-l...

Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025